Compare NKX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKX | ARVN |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.3M | 600.2M |
| IPO Year | 2002 | 2018 |
| Metric | NKX | ARVN |
|---|---|---|
| Price | $10.58 | $7.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $13.93 |
| AVG Volume (30 Days) | 233.0K | ★ 703.7K |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | $12.76 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.40 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.44 | $6.97 |
| 52 Week High | $13.20 | $14.22 |
| Indicator | NKX | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 14.82 | 38.45 |
| Support Level | N/A | N/A |
| Resistance Level | $13.16 | $8.52 |
| Average True Range (ATR) | 0.16 | 0.31 |
| MACD | -0.07 | -0.07 |
| Stochastic Oscillator | 6.69 | 32.09 |
Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.